Navigation Links
Mayo-led research team develop agents that keep insulin working longer
Date:5/7/2010

find IDE inhibitors using sophisticated technologies. They used robots to test hundreds of thousands of compounds at the Laboratory for Drug Discovery in Neurodegeneration (LDDN), a part of Brigham and Women's Hospital and Harvard Medical School. Surprisingly, these modern methods did not identify any good inhibitors, Dr. Leissring says.

"Our robots wound up being powerless for tackling this particular problem," he says. "Ironically, it was an old-fashioned method that made this breakthrough possible."

The old-fashioned approach involved using a technology invented in 1950 to figure which peptide sequence among trillions of possible combinations IDE chops up most efficiently. Benjamin Turk, Ph.D., of Yale University School of Medicine, conducted this critical step. Then, a team of chemists led by Gregory Cuny, Ph.D., director of Medicinal Chemistry at the LDDN, generated a compound that contained the preferred peptide sequence, together with a special chemical group that binds to zinc. The resulting compound is called "Ii1" (IDE inhibitor 1).

Ii1 is about a million times more potent than any previous IDE inhibitors, but additional work will be needed to turn it into a drug suitable for therapeutic use, Dr. Leissring says. In a key step towards this goal, Dr. Leissring, together with Wei-Jen Tang, Ph.D., and other colleagues from the University of Chicago, solved the 3-dimensional crystal structure of Ii1 bound to IDE. This crystal structure will facilitate the development of inhibitors that are more stable in the body than Ii1 is predicted to be.

The structure of IDE is unlike other proteases, the researchers say. It is shaped like a hinged clamshell that opens and shuts, like the well-known video game protagonist, Pac-Man.

The researchers found from their crystal structure that the Ii1 peptide acts like a magnetic latch that holds the clamshell shut. "Think of a coin purse that uses a magnet at the top to
'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 According to ... Vkool.com, this is a comprehensive fitness guide that teaches men ... per week. , Vkool reveals in its review that ... discover:, Ways to gain the maximum ... to build muscle and avoid fat gain , ...
(Date:7/28/2014)... July 28, 2014 TherapySites, ... health professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue to extend ... benefits and promotional offers. , “There has been a ... today. With nearly 3 billion Internet users, it ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 CW4K was ... First Lady Michelle Obama and Partnership for a ... as they join the group's DrinkUP effort, ... water, more often. , The seven organizations added ... Nalgene® Outdoor Products, S’well Bottle, Santa Clara Valley Water ...
(Date:7/28/2014)... July 28, 2014 Footwear etc. is ... styles from Mephisto. With shoes, sandals, and boots that ... products continually provide handmade comfort shoes and ... women have come to rely on the superb value, ... Mephisto shoes and sandals contain the highest quality materials ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2
... Automates IBC Protocol Operations and Addresses Medical Research Compliance ... TOPAZ Technologies, a leading provider of medical research management ... latest software addition to its product line, the Biosafety ... the medical research study protocol process, from protocol inception ...
... still needs doctors, interpretation, , , WEDNESDAY, June 10 ... ability -- and which you can give yourself -- ... tests in detecting early dementia, according to British researchers. ... "shows great promise as a screening test for Alzheimer,s ...
... DALLAS, June 10 When he arrived at Methodist Rehabilitation ... by Guillain-Barre Syndrome and barely able to lift his head. ... therapist and the rehabilitation staff, the 48-year-old father of two ... a walker. "My son said that all he wanted for ...
... Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to ... , - New Study Complements Ongoing Bavituximab Plus Carboplatin/Paclitaxel ... - , , TUSTIN, Calif., June 10 Peregrine ... the ASCO Research Foundation has awarded one of its 2009 ...
... Exclusive Worldwide License to Transdel,s Anti-Cellulite Cosmeceutical Product ... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) ... licensing agreement providing JH Direct with the exclusive ... utilizes Transdel,s patented transdermal delivery system technology, Transdel(TM). ...
... , LOS ALTOS, Calif., June 10 InteKrin Therapeutics ... American Diabetes Association annual meeting in New Orleans demonstrating ... anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy ... , The 4 week double blind placebo controlled ...
Cached Medicine News:Health News:TOPAZ Technologies Introduces Biosafety Software Solution 2Health News:TOPAZ Technologies Introduces Biosafety Software Solution 3Health News:Questionnaire May Help Spot Early Dementia 2Health News:Questionnaire May Help Spot Early Dementia 3Health News:Former Quadriplegic Patient Able to Walk Out of Methodist Rehabilitation Hospital 2Health News:ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer 2Health News:ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer 3Health News:ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer 4Health News:Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product 2Health News:Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product 3Health News:Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product 4Health News:InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting 2Health News:InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting 3
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... and LONDON , July 28, 2014 ... to create and commercialize companion diagnostic using genomic data ...  for non-small cell lung cancer patients  New ... test and is planned to run on Rotor-Gene Q, member of ... enabled by AstraZeneca master framework agreement adds to QIAGEN,s ...
(Date:7/28/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... second quarter 2014 financial results on Monday, August 4, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Monday, August 4 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
...   New product launches are continually occurring across various ... to balance the dueling goals of containing costs and producing ... determining how much to invest, and how to best spend ... primary care launch is spent before during the launch ...
... this week,s 46th Annual Midyear Clinical Meeting and Exhibition ... Health launched BarCode360™ , a solution that supports ... timely and cost efficient to order medications and ensure ... bedside. ASHP has set a goal for ...
Cached Medicine Technology:Launch Spend Insights: Companies Now Invest More in Launch Year Than in Previous 3 Ramp-Up Years Combined 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Liquichek CK/LD Isoenzyme Control features analytes used in cardiac profile testing and protein electrophoresis. Assayed for most methods including instruments, immunoinhibition kits and electrophore...
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
Medicine Products: